Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 13/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.48 |
| ▸ | MAPK6 | Q16659 | 7/20 | 0.48 |
| ▸ | MAPKAPK3 | Q16644 | 6/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.48 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375059 | 0.88 | MAP2K4 (0.46) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5372837 | 0.84 | MAPK1 (0.45) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5379446 | 0.81 | NTRK1 (0.46) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5372753 | 0.80 | MAP2K4 (0.47) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5373023 | 0.78 | MAPK1 (0.41) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5377649 | 0.78 | MAPK1 (0.43) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5380038 | 0.78 | MAPK1 (0.46) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL5376642 | 0.78 | MAP2K4 (0.52) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL3756031 | 0.76 | MAP2K4 (0.67) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 | |
| SCHEMBL6490122 | 0.75 | CSNK1D (0.49) | MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | claimed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | claimed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP2K4 130/4885MAPK1 1/4885MAPK6 31/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPK6 31/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | MAP2K4 3021/4885MAPK1 2816/4885MAPK6 3602/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 58/4885MAPK1 22/4885MAPK6 33/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP2K4 71/4885MAPK1 16/4885MAPK6 31/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP2K4 385/4885MAPK1 52/4885MAPK6 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.